Fiche centre
California Neuroscience Research Medical Group, Inc.
Sherman Oaks — United States
Essais liés4clinical trials
VilleSherman Oakslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03237845
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT03237845 | Safety and Efficacy in Adult Subjects With Acute Migraines | COMPLETED |
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |
| Rimegepant | Migraine | Phase 2/3 | NCT03266588 | Open Label Safety Study in Acute Treatment of Migraine | COMPLETED |